Natallie Kajevu, Ivette Banuelos, Pedro Andrade, Elina Hämäläinen, Laureano Sabatier, Manuel Couyoupetrou, María Luisa Villalba, Luciana Gavernet, Anssi Lipponen, Teemu Natunen, Noora Puhakka, Mikko Hiltunen, Alan Talevi, Asla Pitkänen
{"title":"Mitigation of Acute Seizures and Neuropathology after Traumatic Brain Injury by Structure-Based Discovery-Identified Drugs.","authors":"Natallie Kajevu, Ivette Banuelos, Pedro Andrade, Elina Hämäläinen, Laureano Sabatier, Manuel Couyoupetrou, María Luisa Villalba, Luciana Gavernet, Anssi Lipponen, Teemu Natunen, Noora Puhakka, Mikko Hiltunen, Alan Talevi, Asla Pitkänen","doi":"10.1089/neu.2024.0070","DOIUrl":null,"url":null,"abstract":"<p><p>Our objective was to test the hypothesis that structure-based identified or designed compounds exhibiting neuroprotective, antioxidant, and anti-inflammatory properties <i>in vitro</i> will mitigate early seizures and neuropathology after traumatic brain injury (TBI) <i>in vivo</i>. The neuroprotective and anti-inflammatory effects of 11 compounds identified by computer-assisted approximations were tested <i>in vitro</i> in neuronal microglial co-cultures. Among these, compound FBA exhibited the best neuroprotective (MAP-2, microtubule-associated-protein 2, a neuronal damage biomarker), antioxidative (nitrite production), and anti-inflammatory effects <i>in vitro</i> (all <i>p</i> < 0.01). Consequently, its neuroprotective and antiseizure effects were assessed <i>in vivo</i> in adult male Sprague-Dawley rats exposed to severe lateral fluid-percussion-induced TBI. Rats under continuous video-electroencephalogram monitoring received prophylactic treatment with an intraperitoneal (i.p.) injection of FBA (FBApro, 30 mg/kg) or vehicle (VEH, 48% PEG in 0.9% saline, 3 mL/kg) at 2 and 24 h post-TBI. Rats that developed status epilepticus received 1-2 additional on-demand FBA doses (FBApro+, 100 mg/kg, i.p.) to stop epileptiform activity. FBApro treatment reduced the cortical lesion area (18.9 ± 4.1 mm<sup>2</sup>, <i>n</i> = 7) compared with VEH treatment (24.8 ± 5.7 mm<sup>2</sup>, <i>n</i> = 10, <i>p</i> < 0.05). FBApro treatment also showed a favorable effect on the white matter by reducing plasma levels of pNF-H, a biomarker of axonal injury, compared with VEH treatment (Cohen's delta 0.657). Both FBApro (368 ± 407 s) and FBApro+ (256 ± 327 s) treatments reduced the average cumulative seizure duration compared with VEH (896 ± 703 s, both <i>p</i> < 0.05). The FBApro+ treatment regimen also reduced the mean relative theta and alpha power and increased the mean relative gamma power in the electroencephalogram (<i>p</i> < 0.05). Our data identified FBA as a novel structure-based discovered compound with promising favorable effects on structural and functional recovery after TBI.</p>","PeriodicalId":16512,"journal":{"name":"Journal of neurotrauma","volume":" ","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neurotrauma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/neu.2024.0070","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Our objective was to test the hypothesis that structure-based identified or designed compounds exhibiting neuroprotective, antioxidant, and anti-inflammatory properties in vitro will mitigate early seizures and neuropathology after traumatic brain injury (TBI) in vivo. The neuroprotective and anti-inflammatory effects of 11 compounds identified by computer-assisted approximations were tested in vitro in neuronal microglial co-cultures. Among these, compound FBA exhibited the best neuroprotective (MAP-2, microtubule-associated-protein 2, a neuronal damage biomarker), antioxidative (nitrite production), and anti-inflammatory effects in vitro (all p < 0.01). Consequently, its neuroprotective and antiseizure effects were assessed in vivo in adult male Sprague-Dawley rats exposed to severe lateral fluid-percussion-induced TBI. Rats under continuous video-electroencephalogram monitoring received prophylactic treatment with an intraperitoneal (i.p.) injection of FBA (FBApro, 30 mg/kg) or vehicle (VEH, 48% PEG in 0.9% saline, 3 mL/kg) at 2 and 24 h post-TBI. Rats that developed status epilepticus received 1-2 additional on-demand FBA doses (FBApro+, 100 mg/kg, i.p.) to stop epileptiform activity. FBApro treatment reduced the cortical lesion area (18.9 ± 4.1 mm2, n = 7) compared with VEH treatment (24.8 ± 5.7 mm2, n = 10, p < 0.05). FBApro treatment also showed a favorable effect on the white matter by reducing plasma levels of pNF-H, a biomarker of axonal injury, compared with VEH treatment (Cohen's delta 0.657). Both FBApro (368 ± 407 s) and FBApro+ (256 ± 327 s) treatments reduced the average cumulative seizure duration compared with VEH (896 ± 703 s, both p < 0.05). The FBApro+ treatment regimen also reduced the mean relative theta and alpha power and increased the mean relative gamma power in the electroencephalogram (p < 0.05). Our data identified FBA as a novel structure-based discovered compound with promising favorable effects on structural and functional recovery after TBI.
期刊介绍:
Journal of Neurotrauma is the flagship, peer-reviewed publication for reporting on the latest advances in both the clinical and laboratory investigation of traumatic brain and spinal cord injury. The Journal focuses on the basic pathobiology of injury to the central nervous system, while considering preclinical and clinical trials targeted at improving both the early management and long-term care and recovery of traumatically injured patients. This is the essential journal publishing cutting-edge basic and translational research in traumatically injured human and animal studies, with emphasis on neurodegenerative disease research linked to CNS trauma.